New Drug Regimen Aims To Transform TB Treatment, Improve Health

“The first-ever drug regimen designed to treat both drug-sensitive TB and MDR-TB [multidrug-resistant TB] has reached a critical milestone and will advance to a global Phase III clinical trial — the last, but most important stage of testing before it can be made available,” Mel Spigelman, president and CEO of the Global Alliance for TB Drug Development, writes in the Bill & Melinda Gates Foundation’s “Impatient Optimists” blog. “Scientifically, it would fully validate a new approach to develop TB treatments, one that would reduce the time it takes to develop novel regimens from decades to years. Economically, it would shatter the existing cost-based burdens to expanding MDR-TB care. And, from a human perspective, it would transform TB treatment, improving health and productivity around the world,” he writes (4/23).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.